GlassScriptPhysician profile
Michael N Palanca
NPI 1033663109
$1,019.40
in general payments reported to CMS, 2019-2025
13 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.28 · 2020: $78.03 · 2021: $110 · 2022: $172 · 2023: $32.49 · 2024: $165 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $221.40 | 2025 | Tepezza |
| Abbvie INC. | $196.07 | 2022-2025 | |
| Alcon Vision LLC | $133.23 | 2021-2025 | Tryptyr |
| Bausch & Lomb Americas INC. | $84.61 | 2024-2025 | Miebo, Vyzulta, Envista Mx60 Iol |
| Mallinckrodt Hospital Products INC. | $84.13 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $70.17 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Dompe US, INC. | $63.01 | 2024-2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $55.15 | 2024 | Syfovre |
| Sun Pharmaceutical Industries INC. | $25.95 | 2025 | |
| Allergan, INC. | $23.86 | 2022 | |
| Thea Pharma INC. | $23.30 | 2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $21.28 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Palanca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.